

Pertussis Treatment Market is Projected to US\$ 5.3 Billion with 3.4% CAGR by 2034 | Fact.MR Report

Pertussis Medications and Vaccinations Leading Therapeutic Approaches Driving Stance of Companies in the Market: Fact.MR Study

ROCKVILLE, MD , MD, UNITED STATES, March 14, 2025 /EINPresswire.com/ -- The global [pertussis treatment market](#) is estimated at a value of US\$ 3.8 billion in 2024 and is forecasted to increase to US\$ 5.3 billion by the end of 2034, reveals Fact.MR, a market research and competitive intelligence provider, in its new research report.



Pertussis, also known as whooping cough, is an infectious respiratory disease caused by the *Bordetella pertussis* bacteria. Pertussis mostly affects young children and the older population, and treatment involves medication, vaccination, and supportive care.

Rising prevalence of whooping cough caused by different factors is leading to a high demand for innovative and effective pertussis therapeutic solutions. Drug manufacturers are focused on developing new antibiotics and treatment protocols to combat *Bordetella pertussis* bacteria. For the same, industry giants are heavily investing in research and development efforts. Targeted antibiotic therapies are the frontline treatments for pertussis infection.

Researchers worldwide are also exploring novel antibiotic classes that can demonstrate efficacy against the *Bordetella pertussis* bacteria. Combination therapies are expected to offer enhanced treatment outcomes and reduce the likelihood of resistance. Furthermore, the personalized medication trend is also set to offer lucrative growth opportunities for key companies that are involved in providing pertussis treatment solutions.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10267

Key Takeaways from Market Study

Global demand for pertussis therapeutic solutions is projected to rise at a CAGR of 3.45 from 2024 to 2034.

The market for pertussis treatment in the United States is forecasted at a value of US\$ 1.29 billion in 2024.

Sales of pertussis drugs in South Korea are forecasted to rise at a CAGR of 3.7% through 2034. The market for pertussis medications is estimated at US\$ 1.59 billion in 2024.

Hospital pharmacies are projected to capture 39.1% of the global market share by 2034.

“North America, followed Western Europe, will be key regional markets for pertussis treatment over the next decade,” says a Fact.MR analyst.

Pertussis Treatment Market:

Johnson & Johnson Services Inc.; GlaxoSmithKline, Plc.; Merck & Co. Inc.; Sanofi; Pfizer Inc.; Novartis AG; Panacea Biotech; China National Biotec Group; Changchun Changsheng Life Sciences; Daiichi Sankyo Company Ltd.; Mylan NV; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Mitsubishi Tanabe Pharma; Astellas Pharma; Shenzhen KangTai Biological Products.

Collaborations Key Trend in Pertussis Treatment Market:

Pharmaceutical companies, research institutions, and government healthcare organizations are collaborating for the development and discovery of advanced pertussis medications. These collaborations are aimed at becoming more effective in reducing the ill effects of pertussis and boosting the profits of several stakeholders. International agreements are aimed at the more effective addressing and managing of pertussis globally. These are expected to increase the sales of pertussis therapeutic solutions, especially in high-potential markets such as Latin America and Asia Pacific.

According to an article under scientific reports published by Nature on 16th March 2023, a pangenome approach-based loop-mediated isothermal amplification assay is proving effective for specific and early detection of pertussis infection.

Get Customization on this Report for Specific Research Solutions:

https://www.factmr.com/connectus/sample?flag=S&rep_id=10267

Pertussis Treatment Market News:

According to a press release by EurekAlert, researchers at the American Society for Biochemistry and Molecular Biology discovered a crucial biomolecule involved in pertussis infection. The

research has the potential to contribute towards the development of a new vaccine or drug for whooping cough.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global pertussis treatment market, presenting historical demand data (2019 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights on the market based treatment type (medications, vaccinations, supportive treatments, others), diagnosis (blood tests, chest X-rays, nose or throat culture & tests), mode of purchase (Rx, OTC), route of administration (oral, parenteral, others), disease stage (incubation stage, catarrhal stage, paroxysmal stage, convalescent stage), and distribution channel (hospital pharmacies, online pharmacies, retail pharmacies), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Check out More Related Studies Published by Fact.MR:

The global [allergic rhinitis treatment market size](#) is estimated at US\$ 16.03 billion in 2024 and is projected to reach a valuation of US\$ 23.38 billion by the end of 2034, advancing at a CAGR of 3.8% over the next ten years.

The global [polyneuropathy treatment market size](#) is valued at US\$ 2.05 billion in 2024 and is projected to expand at a CAGR of 4.9% to reach US\$ 3.31 billion by 2034-end.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:

11140 Rockville Pike
Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

Sales Team: sales@factmr.com

Follow Us: [LinkedIn](#) | [Twitter](#) | [Blog](#)

S. N. Jha

Fact.MR

+1 628-251-1583

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/793789756>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.